Koru Medical announces feasibility study for rare disease therapy

The company states: “KORU Medical announced a collaboration with a global pharmaceutical manufacturer to initiate a feasibility study with KORU’s Freedom Infusion System for an already commercialized rare disease therapy. Upon successful completion of the feasibility study, KORU Medical intends to develop a customized Freedom System that will deliver this large volume therapy via subcutaneous administration. Healthcare providers administer this rare disease drug in the growing ambulatory infusion center and ambulatory infusion suite setting in the United States and the hospital setting in the European Union.”